Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022

References

1. 1.↵
   1. Miller KD,
   2. Ostrom QT,
   3. Kruchko C, et al

   . Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 2021;71:381–406 doi:10.3322/caac.21693 pmid:34427324

   CrossRefPubMed
2. 2.↵
   World Health Organization. Central Nervous System Tumors. WHO Classification of Tumours Online. 5th ed. https://tumourclassification.iarc.who.int/welcome/. Accessed January 16, 2023
3. 3.↵
   1. Velasco R,
   2. Mercadal S,
   3. Vidal N

   , et al; GELTAMO and GENOSEN Group. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol 2020;148:545–54 doi:10.1007/s11060-020-03547-z pmid:32524392

   CrossRefPubMed
4. 4.↵
   World Health Organization. Hematolymphoid Tumours. WHO Classification of Tumours Online. 5th ed. https://tumourclassification.iarc.who.int/welcome/. Accessed January 16, 2023
5. 5.↵
   1. Tang YZ,
   2. Booth TC,
   3. Bhogal P, et al

   . Imaging of primary central nervous system lymphoma. Clin Radiol 2011;66:768–77 doi:10.1016/j.crad.2011.03.006 pmid:21513925

   CrossRefPubMed
6. 6.↵
   1. Mansour A,
   2. Qandeel M,
   3. Abdel-Razeq H, et al

   . MR imaging features of intracranial primary CNS lymphoma in immune competent patients. Cancer Imaging 2014;14:1–9 doi:10.1186/1470-7330-14-22 pmid:25608570

   CrossRefPubMed
7. 7.↵
   1. Pons-Escoda A,
   2. Garcia-Ruiz A,
   3. Naval-Baudin P, et al

   . Presurgical identification of primary central nervous system lymphoma with normalized time-intensity curve: a pilot study of a new method to analyze DSC-PWI. AJNR Am J Neuroradiol 2020;41:1816–24 doi:10.3174/ajnr.A6761 pmid:32943424

   Abstract/FREE Full Text
8. 8.↵
   1. Pons-Escoda A,
   2. García-Ruíz A,
   3. Naval-Baudin P, et al

   . Diffuse large B-cell Epstein-Barr virus-positive primary CNS lymphoma in non-AIDS patients: high diagnostic accuracy of DSC perfusion metrics. AJNR Am J Neuroradiol 2022;43:1567–74 doi:10.3174/ajnr.A7668 pmid:36202547

   Abstract/FREE Full Text
9. 9.↵
   1. Cree IA

   . The WHO Classification of Haematolymphoid Tumours. Leukemia 2022;36:1701–02 doi:10.1038/s41375-022-01625-x pmid:35732830

   CrossRefPubMed
10. 10.↵
    1. Li W

    1. Li W

    . The 5(th) Edition of the World Health Organization Classification of Hematolymphoid Tumors. In: Li W. ed. Brisbane (AU) 2022
11. 11.↵
    1. Haldorsen IS,
    2. Espeland A,
    3. Larsson E-M

    . Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011;32:984–92 doi:10.3174/ajnr.A2171 pmid:20616176

    Abstract/FREE Full Text
12. 12.↵
    1. Deckert M,
    2. Brunn A,
    3. Montesinos-Rongen M, et al

    . Primary lymphoma of the central nervous system: a diagnostic challenge. Hematol Oncol 2014;32:57–67 doi:10.1002/hon.2087 pmid:23949943

    CrossRefPubMed
13. 13.↵
    1. Brunn A,
    2. Nagel I,
    3. Montesinos-Rongen M, et al

    . Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol 2013;126:603–05 doi:10.1007/s00401-013-1169-7 pmid:24061549

    CrossRefPubMed
14. 14.↵
    1. Jhaveri MD,
    2. Osborn AG,
    3. Salzman KL

    1. Jhaveri MD

    . Chapter 173: diffuse large B-cell lymphoma. In: Jhaveri MD, Osborn AG, Salzman KL. Diagnostic Imaging: Brain. 4th ed. Elsevier; 2020:602–06
15. 15.↵
    1. Sakata A,
    2. Okada T,
    3. Yamamoto A, et al

    . Primary central nervous system lymphoma: is absence of intratumoral hemorrhage a characteristic finding on MRI? Radiol Oncol 2015;49:128–34 doi:10.1515/raon-2015-0007 pmid:26029023

    CrossRefPubMed
16. 16.↵
    1. Barajas RF,
    2. Politi LS,
    3. Anzalone N, et al

    . Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 2021;23:1056–71 doi:10.1093/neuonc/noab020 pmid:33560416

    CrossRefPubMed
17. 17.↵
    1. Lee MD,
    2. Baird GL,
    3. Bell LC, et al

    . Utility of percentage signal recovery and baseline signal in DSC-MRI optimized for relative CBV measurement for differentiating glioblastoma, lymphoma, metastasis, and meningioma. AJNR Am J Neuroradiol 2019;40:1145–450 doi:10.3174/ajnr.A6153 pmid:31371360

    CrossRefPubMed
18. 18.↵
    1. Xing Z,
    2. You RX,
    3. Li J, et al

    . Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol 2014;24:329–36 doi:10.1007/s00062-013-0255-5 pmid:23994941

    CrossRefPubMed
19. 19.↵
    1. Valles FE,
    2. Perez-Valles CL,
    3. Regalado S, et al

    . Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol 2013;34:35–40 doi:10.3174/ajnr.A3165 pmid:22936096

    Abstract/FREE Full Text
20. 20.↵
    1. Mora P,
    2. Majós C,
    3. Castañer S, et al

    . 1H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery. Eur Radiol 2014;24:2895–905 doi:10.1007/s00330-014-3308-5 pmid:25027839

    CrossRefPubMed
21. 21.↵
    1. Husseini L,
    2. Saleh A,
    3. Reifenberger G, et al

    . Inflammatory demyelinating brain lesions heralding primary CNS lymphoma. Can J Neurol Sci 2012;39:6–10 doi:10.1017/S0317167100012610 pmid:22384490

    CrossRefPubMed
22. 22.↵
    1. Levine AM

    . Lymphoma complicating immunodeficiency disorders. Ann Oncol 1994;5(5 Supple 2):29–35 doi:10.1093/annonc/5.suppl_2.s29 pmid:8204517

    CrossRefPubMed
23. 23.↵
    1. Gandhi MK,
    2. Hoang T,
    3. Law SC, et al

    . EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood 2021;137:1468–77 doi:10.1182/blood.2020008520 pmid:33202420

    CrossRefPubMed
24. 24.↵
    1. Mahale P,
    2. Shiels MS,
    3. Lynch CF, et al

    . Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant 2018;18:453–61 doi:10.1111/ajt.14465 pmid:28805292

    CrossRefPubMed
25. 25.↵
    1. Verdu-Bou M,
    2. Tapia G,
    3. Hernandez-Rodriguez A, et al

    . Clinical and therapeutic implications of Epstein–Barr virus in HIV-related lymphomas. Cancers (Basel) 2021;13:5534 doi:10.3390/cancers13215534 pmid:33561018

    CrossRefPubMed
26. 26.↵
    1. Kaulen LD,
    2. Karschnia P,
    3. Dietrich J, et al

    . Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol 2020;149:153–59 doi:10.1007/s11060-020-03583-9 pmid:32683530

    CrossRefPubMed
27. 27.↵
    1. Mancuso S,
    2. Carlisi M,
    3. Santoro M, et al

    . Immunosenescence and lymphomagenesis. Immun Ageing 2018;15:1–7 doi:10.1186/s12979-018-0130-y pmid:29387133

    CrossRefPubMed
28. 28.↵
    1. Barosi G

    . An immune dysregulation in MPN. Curr Hematol Malig Rep 2014;9:331–39 doi:10.1007/s11899-014-0227-0 pmid:25139710

    CrossRefPubMed
29. 29.↵
    1. Suh CH,
    2. Kim HS,
    3. Lee SS, et al

    . Atypical imaging features of primary central nervous system lymphoma that mimics glioblastoma: utility of intravoxel incoherent motion MR imaging. Radiology 2014;272:504–13 doi:10.1148/radiol.14131895 pmid:24697149

    CrossRefPubMed
30. 30.↵
    1. Sauter A,
    2. Faul C,
    3. Bitzer M, et al

    . Imaging findings in immunosuppressed patients with Epstein Barr virus-related B cell malignant lymphoma. Am J Roentgenol 2010;194:W141–49 doi:10.2214/AJR.09.3264 pmid:20093565

    CrossRefPubMed
31. 31.↵
    1. Patsalides AD,
    2. Atac G,
    3. Hedge U, et al

    . Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology 2005;237:265–73 doi:10.1148/radiol.2371041087 pmid:16100084

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Tateishi U,
    2. Terae S,
    3. Ogata A, et al

    . MR imaging of the brain in lymphomatoid granulomatosis. AJNR Am J Neuroradiol 2001;22:1283–90 pmid:11498415

    Abstract/FREE Full Text
33. 33.↵
    1. De Graaff HJ,
    2. Wattjes MP,
    3. Rozemuller-Kwakkel AJ, et al

    . Fatal B-cell lymphoma following chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. JAMA Neurol 2013;70:915–18 doi:10.1001/jamaneurol.2013.2016 pmid:23649857

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Dang YL,
    2. Kok HK,
    3. McKelvie PA, et al

    . Chronic lymphocytic infiltration with pontine perivascular enhancement responsive to steroids (CLIPPERS) and its association with Epstein‐Barr virus (EBV)-related lymphomatoid granulomatosis: a case report. BMC Neurol 2021;21:80 doi:10.1186/s12883-021-02110-1 pmid:33602163

    CrossRefPubMed
35. 35.↵
    1. Fonkem E,
    2. Dayawansa S,
    3. Stroberg E, et al

    . Neurological presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients. BMC Neurol 2016;16:9 doi:10.1186/s12883-015-0509-8 pmid:26849888

    CrossRefPubMed
36. 36.↵
    1. Baehring JM,
    2. Henchcliffe C,
    3. Ledezma CJ, et al

    . Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system. J Neurol Neurosurg Psychiatry 2005;76:540–44 doi:10.1136/jnnp.2003.033662 pmid:15774442

    Abstract/FREE Full Text
37. 37.↵
    1. Yamamoto A,
    2. Kikuchi Y,
    3. Homma K, et al

    . Characteristics of intravascular large B-cell lymphoma on cerebral MR imaging. AJNR Am J Neuroradiol 2012;33:292–96 doi:10.3174/ajnr.A2770 pmid:22173763

    Abstract/FREE Full Text
38. 38.↵
    1. Quinn ZL,
    2. Zakharia K,
    3. Schmid JL, et al

    . Primary dural diffuse large B-cell lymphoma: a comprehensive review of survival and treatment outcomes. Clin Lymphoma Myeloma Leuk 2020;20:e105–12 doi:10.1016/j.clml.2019.09.600 pmid:31902733

    CrossRefPubMed
39. 39.↵
    1. Pons Escoda A,
    2. Naval Baudin P,
    3. Mora P, et al

    . Imaging of skull vault tumors in adults. Insights Imaging 2020;11:23 doi:10.1186/s13244-019-0820-9 pmid:32056014

    CrossRefPubMed
40. 40.↵
    1. Smith AB,
    2. Horkanyne-Szakaly I,
    3. Schroeder JW, et al

    . From the Radiologic Pathology Archives: mass lesions of the dura—beyond meningioma, radiologic-pathologic correlation. Radiographics 2014;34:295–312 doi:10.1148/rg.342130075 pmid:24617680

    CrossRefPubMed
41. 41.↵
    1. Jahnke K,
    2. Schilling A,
    3. Heidenreich J, et al

    . Radiologic morphology of low-grade primary central nervous system lymphoma in immunocompetent patients. AJNR Am J Neuroradiol 2005;26:2446–54 pmid:16286384

    PubMedWeb of Science
42. 42.↵
    1. Magaki S,
    2. Satyadev R,
    3. Chen Z, et al

    . Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement. Brain Tumor Pathol 2022;39:25–34 doi:10.1007/s10014-021-00415-0 pmid:34791573

    CrossRefPubMed
43. 43.↵
    1. Menon MP,
    2. Nicolae A,
    3. Meeker H, et al

    . Primary CNS T-cell lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis. Am J Surg Pathol 2015;39:1719–29 doi:10.1097/PAS.0000000000000503 pmid:26379152

    CrossRefPubMed
44. 44.↵
    1. Izquierdo C,
    2. Velasco R,
    3. Vidal N, et al

    . Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma: analysis of 7 cases and systematic review of the literature. Neuro Oncol 2016;18:707–15 doi:10.1093/neuonc/nov197 pmid:26415875

    CrossRefPubMed
45. 45.↵
    1. Hatanpaa KJ,
    2. Fuda F,
    3. Koduru P, et al

    . Lymphomatosis cerebri: a diagnostic challenge. JAMA Neurol 2015;72:1066–67 doi:10.1001/jamaneurol.2015.1149 pmid:26147788

    CrossRefPubMed
46. 46.↵
    1. Li L,
    2. Rong JH,
    3. Feng J

    . Neuroradiological features of lymphomatosis cerebri: a systematic review of the English literature with a new case report. Oncol Lett 2018;16:1463–74 doi:10.3892/ol.2018.8839 pmid:30008825

    CrossRefPubMed
47. 47.↵
    1. Yu H,
    2. Gao B,
    3. Liu J, et al

    . Lymphomatosis cerebri: a rare variant of primary central nervous system lymphoma and MR imaging features. Cancer Imaging 2017;17:26 doi:10.1186/s40644-017-0128-2 pmid:28982392

    CrossRefPubMed
48. 48.↵
    1. Nagpal S,
    2. Glantz MJ,
    3. Recht L

    . Treatment and prevention of secondary CNS lymphoma. Semin Neurol 2010;30:263–72 doi:10.1055/s-0030-1255222 pmid:20577933

    CrossRefPubMed
49. 49.↵
    1. Ferreri AJM,
    2. Doorduijn JK,
    3. Re A

    , et al; International Extranodal Lymphoma Study Group (IELSG). MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol 2021;8:e110–21 doi:10.1016/S2352-3026(20)30366-5 pmid:33513372

    CrossRefPubMed
50. 50.↵
    1. Bobillo S,
    2. Khwaja J,
    3. Ferreri AJM

    , et al. Prevention and management of secondary central nervous system lymphoma. Haematologica 2022. Nov 17 doi:10.3324/haematol.2022.281457 pmid:36384246

    CrossRefPubMed